Endocrinology Search
Endocrinology Endocrinology
hypomagnesemia%20-and-%20hypermagnesemia
HYPOMAGNESEMIA & HYPERMAGNESEMIA
Hypomagnesemia is having a serum magnesium concentration of <1.3 mEq/L.
Patients with mild hypomagnesemia is asymptomatic and have usually a serum Mg >0.5 mmol/L. While those with moderate-severe hypomagnesemia, the patient is symptomatic and have serum Mg <5 mmol/L.
Hypermagnesemia signs and symptoms usually do not appear unless Mg >2 mmol/L (5 mg/dL). It rarely occurs and usually iatrogenic.

Hypomagnesemia & Hypermagnesemia Drug Information

Drug Information

Indication: Acute hypomagnesaemia. Prevention of hypomagnesaemia in patients receiving TPN. Prevention & treatment of ...

Proscal
calcium + magnesium + phosphorus + vitamin D3

Indication: Nutritional supplement as Ca source for healthy bones.

Cal-Mag
calcium + magnesium + vitamin D
Obical
calcium + fructo-oligosaccharide + magnesium oxide...
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Low-carb diet ups energy expenditure during weight loss maintenance
Stephen Padilla, 28 Nov 2018
A low-carbohydrate diet increases energy expenditure during weight loss maintenance, consistent with the carbohydrate-insulin model, a study has shown. This metabolic effect may contribute to the success of obesity treatment, particularly among those with high insulin secretion.
Higher fasting glucose ups post-stroke mortality in Chinese diabetic patients
Natalia Reoutova, 07 Jul 2020

A hospital-based observational cohort study finds an association between higher fasting blood glucose (FBG) levels and unfavourable outcomes, including death, among Chinese patients with diabetes mellitus (DM) following acute ischaemic stroke (AIS).
Liraglutide add-on to metformin sustained glycaemic control in T2D
Elaine Soliven, 06 Jul 2020
Adding liraglutide to metformin led to a significantly longer duration of glycaemic control in patients with type 2 diabetes (T2D) compared with an oral antidiabetic drug (OAD), according to the LIRA-PRIME* study presented at ADA 2020.